In Vitro Blood-Brain Barrier Modeling adapted for Peripheral Blood Mononuclear Cell Transmigration from HIV-Positive Patients for Clinical Research on Therapeutic Drug Intervention

被引:0
|
作者
Oda, Robert [1 ]
Shiramizu, Bruce [2 ]
Agsalda-Garcia, Melissa [2 ]
Kettlewell, Joanna [2 ]
Wojna, Valerie [3 ]
机构
[1] Univ Hawaii Manoa, Coll Trop Agr & Human Resources, Dept Mol Biosci & Bioengn, Honolulu, HI 96822 USA
[2] Univ Hawaii, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI USA
[3] Univ Puerto Rico, Neurol Div, Dept Med, Med Sci Campus, San Juan, PR 00936 USA
关键词
HIV; Cognition; Blood-brain barrier; Neurocognition; Brain; MONOCYTES; DNA; DEMENTIA; HAART;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: HIV-associated cognitive impairment (HACI) continues to persist for HIV-seropositive individuals who are on antiretroviral therapy (ART). HACI develops in part when HIV-infected monocytes (MOs) transmigrate through the blood-brain barrier (BBB) and secrete pro-inflammatory cytokines and chemokines, which leads to neuronal damage. In vitro BBB models are important tools that can elucidate mechanisms of MO transmigration. Previously described in vitro BBB models relied on pathology specimens, resulting in potentially variable and inconsistent results. This project reports on a reliable and consistent alternative in vitro BBB model that has the potential to be used in clinical research intervention studies analyzing the effects of ART on the BBB and on MO transmigration. Methods: A bilayer BBB model was established with commercially available astrocytes and endothelial cells on a 3 mu m PET membrane insert to allow the contact of astrocytic foot processes with endothelial cells. Inserts were cultured in growth medium for 7 days before exposure to HIV- or HIV+ peripheral blood mononuclear cells (PBMCs). PBMCs were allowed to transmigrate across the BBB for 24 hours. Results: Confluency and integrity measurements by trans-endothelial electrical resistance (TEER) (136.7 +/- 18.3 Omega/cm(2)) and permeability (5.64 +/- 2.20%) verified the integrity of the in vitro BBB model. Transmigrated MOs and non-MOs were collected and counted (6.0x10(4) MOs; 1.1x10(5) non-MOs). Markers indicative of glial fibrillary acidic protein (GFAP), von Willebrand factor (vWF), and p-glycoprotein (Pgp) were revealed in immunofluorescence staining (IF), indicating BBB phenotype and functionality. Conclusion: Potential applications for this model include assessing the HIV DNA copy numbers of transmigrated cells (pre- and post-targeted ART) and understanding the role of oxidative stress related to HIV DNA and HACI.
引用
收藏
页码:155 / 159
页数:5
相关论文
共 50 条
  • [31] Peripheral blood CD4+T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line
    Bahbouhi, Bouchaib
    Berthelot, Laureline
    Pettre, Segolene
    Michel, Laure
    Wiertlewski, Sandrine
    Weksler, Babette
    Romero, Ignacio-Andres
    Miller, Florence
    Couraud, Pierre-Olivier
    Brouard, Sophie
    Laplaud, David-Axel
    Soulillou, Jean-Paul
    JOURNAL OF LEUKOCYTE BIOLOGY, 2009, 86 (05) : 1049 - 1063
  • [32] Brain Barriers and brain fluids research in 2020 and the fluids and barriers of the CNS thematic series on advances in in vitro modeling of the blood-brain barrier and neurovascular unit
    Keep, Richard F.
    Jones, Hazel C.
    Drewes, Lester R.
    FLUIDS AND BARRIERS OF THE CNS, 2021, 18 (01)
  • [33] West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: Transmigration across the in vitro blood-brain barrier
    Verma, Saguna
    Lo, Yeung
    Chapagain, Mod
    Lum, Stephanie
    Kumar, Mukesh
    Gurjav, Ulziijargal
    Luo, Haiyan
    Nakatsuka, Austin
    Nerurkar, Vivek R.
    VIROLOGY, 2009, 385 (02) : 425 - 433
  • [34] Circulating dendritic cells of patients with multiple sclerosis show inflammation-dependent gene expression changes following transmigration across an in vitro blood-brain barrier
    De Laere, M.
    Van Laere, S.
    Derdelinckx, J.
    Willekens, B.
    Berneman, Z.
    Cools, N.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 396 - 396
  • [35] Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model
    Verite, Julie
    Page, Guylene
    Paccalin, Marc
    Julian, Adrien
    Janet, Thierry
    PLOS ONE, 2018, 13 (08):
  • [36] Effect of Sera from Bickerstaff Brainstem Encephalitis and Miller Fisher Syndrome Patients Against Human Blood-Brain Barrier and Blood-Nerve Barrier In Vitro Models
    Saito, Kazuyuki
    Shimizu, Fumitaka
    Koga, Michiaki
    Sano, Yasuteru
    Haruki, Hiroyo
    Maeda, Toshihiko
    Abe, Masaaki
    Tasaki, Ayako
    Suzuki, Seiko
    Kusunoki, Susumu
    Mizusawa, Hidehiro
    Kanda, Takashi
    NEUROLOGY, 2012, 78
  • [37] In vitro drug-induced cytokine release from peripheral blood mononuclear cells of patients with delayed-type drug hypersensitivity
    Beeler, A.
    Lochmatterl, P.
    Kawabata, T.
    Pichler, WJ.
    SWISS MEDICAL WEEKLY, 2008, 138 : 45S - 45S
  • [38] In vitro drug-induced cytokine release from peripheral blood mononuclear cells of patients with delayed-type drug hypersensitivity
    Lochmatter, P.
    Beeler, A.
    Kawabata, T.
    Gerber, B.
    Pichler, W.
    ALLERGY, 2008, 63 : 76 - 76
  • [39] Serum from MS patients treated with interferon β-1b leads to a stabilisation of the blood-brain barrier in vitro
    Mueller, M.
    Frese, A.
    Nassenstein, I.
    Hoppen, M.
    Marziniak, M.
    Ringelstein, E. B.
    Kim, K. S.
    Schaebitz, W. R.
    Kraus, J.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S240 - S240
  • [40] Decreased recovery of replication-competent HIV-1 from peripheral blood mononuclear cell-derived monocyte/macrophages of HIV-positive patients after 3 years on highly active antiretroviral therapy
    Belmonte, L
    Baré, P
    Picchio, GR
    Bianco, RP
    Pinto, MD
    Corti, M
    Villafañe, MF
    de Bracco, MME
    Ruibal-Ares, BH
    AIDS, 2002, 16 (09) : 1289 - 1292